Microbiota dysbiosis in select human cancers: Evidence of association and causality

Seminars in Immunology

Volumn 32, Issue , 2017, Pages 25-34

  Chen, Jie ^a   Domingue, Jada C ^b   Sears, Cynthia L ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOFILM; CAUSALITY; COLORECTAL CANCER; DISEASE ASSOCIATION; DYSBIOSIS; HEAD AND NECK CANCER; HUMAN; INFECTIOUS AGENT; INTESTINE FLORA; LUNG; LUNG CANCER; MICROFLORA; MOUTH FLORA; NONHUMAN; PANCREAS CANCER; REVIEW; ANIMAL; COMPLICATION; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MOUTH; MUCOSA; NEOPLASM; PHYSIOLOGY; SYMBIOSIS;

ANIMALS; DYSBIOSIS; HUMANS; INTESTINES; MICROBIOTA; MOUTH; MUCOUS MEMBRANE; NEOPLASMS; SYMBIOSIS;

EID: 85027421119     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2017.08.001     Document Type: Review

References (114)

1. Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012 Reviewed in May 2017) http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Sears, C.L., Garrett, W.S., Microbes, microbiota, and colon cancer. Cell Host Microbe 15:3 (2014), 317–328.
3. Schwabe, R.F., Jobin, C., The microbiome and cancer. Nat. Rev. Cancer 13:11 (2013), 800–812.
4. Peek, R.M., Blaser, M.J., Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2:1 (2002), 28–37.
5. Sears, C.L., Pardoll, D.M., Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J. Infect. Dis. 203:3 (2011), 306–311.
6. Hjalgrim, H., Askling, J., Rostgaard, K., et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N. Engl. J. Med. 349:14 (2003), 1324–1332.
7. Nghiem, P.T., Bhatia, S., Lipson, E.J., et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374:26 (2016), 2542–2552.
8. Chakravorty, S., Helb, D., Burday, M., et al. A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J. Microbiol. Methods 69:2 (2007), 330–339.
9. Langille, M.G., Zaneveld, J., Caporaso, J.G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31:9 (2013), 814–821.
10. The Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486:7402 (2012), 207–214.
11. Arumugam, M., Raes, J., Pelletier, E., et al. Enterotypes of the human gut microbiome. Nature 473:7346 (2011), 174–180.
12. Drewes, J.L., Housseau, F., Sears, C.L., Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. Br. J. Cancer 115:3 (2016), 273–280.
13. Brenner, H., Kloor, M., Pox, C.P., Colorectal cancer. Lancet 383:9927 (2014), 1490–1502.
14. Siegel, R.L., Fedewa, S.A., Anderson, W.F., et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J. Natl. Cancer Inst., 109(8), 2017.
15. Fodde, R., Smits, R., Clevers, H., APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1:1 (2001), 55–67.
16. Jasperson, K.W., Tuohy, T.M., Neklason, D.W., et al. Hereditary and familial colon cancer. Gastroenterology 138:6 (2010), 2044–2058.
17. Gagliani, N.H.B., Huber, S., Elinav, E., Flavell, R., The fire within: microbes inflame tumors. Cell 157 (2014), 776–783.
18. Thiele Orberg, E., Fan, H., Tam, A.J., et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol, 2016 Epub 2016.53.
19. Wu, S., Rhee, K.J., Albesiano, E., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15:9 (2009), 1016–1022.
20. Goodwin, A.C., Destefano Shields, C.E., Wu, S., et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 108:37 (2011), 15354–15359.
21. Arthur, J.C., Perez-Chanona, E., Muhlbauer, M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:6103 (2012), 120–123.
22. Huycke, M.M., Abrams, V., Moore, D.R., Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23:3 (2002), 529–536.
23. Dejea, C.M., Wick, E.C., Hechenbleikner, E.M., et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 111:51 (2014), 18321–18326.
24. Kostic, A.D., Chun, E., Robertson, L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune micro environment. Cell Host Microbe 14:2 (2013), 207–215.
25. Dejea, C., Wick, E., Sears, C.L., Bacterial oncogenesis in the colon. Future Microbiol. 8:4 (2013), 445–460.
26. Johnson, C.H., Dejea, C.M., Edler, D., et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 21:6 (2015), 891–897.
27. Louis, P., Hold, G.L., Flint, H.J., The gut microbiota: bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12:10 (2014), 661–672.
28. Hall-Stoodley, L., Costerton, J.W., Stoodley, P., Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:2 (2004), 95–108.
29. Swidsinski, A., Weber, J., Loening-Baucke, V., et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43:7 (2005), 3380–3389.
30. Ahn, J., Sinha, R., Pei, Z., et al. Human gut microbiome and risk for colorectal cancer. J. Natl. Cancer Inst. 105:24 (2013), 1907–1911.
31. Kostic, A.D., Gevers, D., Pedamallu, C.S., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22:2 (2012), 292–298.
32. Castellarin, M., Warren, R.L., Freeman, J.D., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22:2 (2012), 299–306.
33. Vogtmann, E., Goedert, J.J., Epidemiologic studies of the human microbiome and cancer. Br. J. Cancer 114:3 (2016), 237–242.
34. Flynn, K.J., Baxter, N.T., Schloss, P.D., Metabolic and community synergy of oral bacteria in colorectal cancer. mSphere, 1(3), 2016 Epub 00102-16.
35. Feng, Q., Liang, S., Jia, H., et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat. Commun., 6, 2015, 6528.
36. Zackular, J.P., Rogers, M.A., Ruffin, M.T.t., et al. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev. Res. (Phila) 7:11 (2014), 1112–1121.
37. Yang, Y., Weng, W., Peng, J., et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of microRNA-21. Gastroenterology 152:4 (2017), 851–866 e824.
38. Tomkovich, S., Yang, Y., Winglee, K., et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 77:10 (2017), 2620–2632.
39. Rubinstein, M.R., Wang, X., Liu, W., et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14:2 (2013), 195–206.
40. Galvao-Moreira, L.V., da Cruz, M.C., Oral microbiome, periodontitis and risk of head and neck cancer. Oral Oncol. 53 (2016), 17–19.
41. Chi, A.C., Day, T.A., Neville, B.W., Oral cavity and oropharyngeal squamous cell carcinoma–an update. CA. Cancer J. Clin. 65:5 (2015), 401–421.
42. Schmidt, B.L., Kuczynski, J., Bhattacharya, A., et al. Changes in abundance of oral microbiota associated with oral cancer. PLoS One, 9(6), 2014, e98741.
43. Printz, C., Poor oral health tied to oral HPV infection. Cancer, 119(24), 2013, 4215.
44. Homann, N., Jousimies-Somer, H., Jokelainen, K., et al. High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and pathogenetic implications. Carcinogenesis 18:9 (1997), 1739–1743.
45. Ma, Y., Madupu, R., Karaoz, U., et al. Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets. J. Virol. 88:9 (2014), 4786–4797.
46. Tezal, M., Scannapieco, F.A., Wactawski-Wende, J., et al. Local inflammation and human papillomavirus status of head and neck cancers. Arch. Otolaryngol. Head Neck Surg. 138:7 (2012), 669–675.
47. Mirghani, H., Amen, F., Moreau, F., et al. Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?. Oral Oncol. 51:3 (2015), 229–236.
48. D'Souza, G., Kreimer, A.R., Viscidi, R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356:19 (2007), 1944–1956.
49. Guerrero-Preston, R., Godoy-Vitorino, F., Jedlicka, A., et al. 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget 7:32 (2016), 51320–51334.
50. Inaba, H., Sugita, H., Kuboniwa, M., et al. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cell. Microbiol. 16:1 (2014), 131–145.
51. Mao, S., Park, Y., Hasegawa, Y., et al. Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis. Cell. Microbiol. 9:8 (2007), 1997–2007.
52. Hajishengallis, G., Lamont, R.J., Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol 27:6 (2012), 409–419.
53. Gong, H., Shi, Y., Zhou, X., et al. Microbiota in the throat and risk factors for laryngeal carcinoma. Appl. Environ. Microbiol. 80:23 (2014), 7356–7363.
54. Pushalkar, S., Ji, X., Li, Y., et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol., 12, 2012, 144.
55. Byakodi, R., Krishnappa, R., Keluskar, V., et al. The microbial flora associated with oral carcinomas. Quintessence Int. 42:9 (2011), e118–e123.
56. Mager, D.L., Haffajee, A.D., Devlin, P.M., et al. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J. Transl. Med., 3, 2005, 27.
57. Pushalkar, S., Mane, S.P., Ji, X., et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol. Med. Microbiol. 61:3 (2011), 269–277.
58. Xu, Y., Teng, F., Huang, S., et al. Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy. Arch. Oral Biol. 59:2 (2014), 176–186.
59. Wang, H., Funchain, P., Bebek, G., et al. Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Med., 9(1), 2017, 14.
60. Hooper, S.J., Crean, S.J., Fardy, M.J., et al. A molecular analysis of the bacteria present within oral squamous cell carcinoma. J. Med. Microbiol. 56:Pt 12 (2007), 1651–1659.
61. Meurman, J.H., Uittamo, J., Oral micro-organisms in the etiology of cancer. Acta Odontol. Scand. 66:6 (2008), 321–326.
62. Kim, J., Amar, S., Periodontal disease and systemic conditions: a bidirectional relationship. Odontology 94:1 (2006), 10–21.
63. Kerr, A.R., The oral microbiome and cancer. J. Dent. Hyg. 89:Suppl. 1 (2015), 20–23.
64. Ahn, J., Segers, S., Hayes, R.B., Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogenesis 33:5 (2012), 1055–1058.
65. Michaud, D.S., Kelsey, K.T., Papathanasiou, E., et al. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study. Ann. Oncol. 27:5 (2016), 941–947.
66. Ilic, M., Ilic, I., Epidemiology of pancreatic cancer. World J. Gastroenterol. 22:44 (2016), 9694–9705.
67. Bosetti, C., Bertuccio, P., Negri, E., et al. Pancreatic cancer: overview of descriptive epidemiology. Mol. Carcinog. 51:1 (2012), 3–13.
68. Li, D., Xie, K., Wolff, R., et al. Pancreatic cancer. Lancet 363:9414 (2004), 1049–1057.
69. Shin, E.J., Canto, M.I., Pancreatic cancer screening. Gastroenterol. Clin. North Am. 41:1 (2012), 143–157.
70. Michaud, D.S., Joshipura, K., Giovannucci, E., et al. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J. Natl. Cancer Inst. 99:2 (2007), 171–175.
71. Otomo-Corgel, J., Pucher, J.J., Rethman, M.P., et al. State of the science: chronic periodontitis and systemic health. J. Evid. Based Dent. Pract. 12:Suppl. 3 (2012), 20–28.
72. Hujoel, P.P., Drangsholt, M., Spiekerman, C., et al. An exploration of the periodontitis-cancer association. Ann. Epidemiol. 13:5 (2003), 312–316.
73. Farrell, J.J., Zhang, L., Zhou, H., et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61:4 (2012), 582–588.
74. Torres, P.J., Fletcher, E.M., Gibbons, S.M., et al. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ, 3, 2015, e1373.
75. Michaud, D.S., Izard, J., Wilhelm-Benartzi, C.S., et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62:12 (2013), 1764–1770.
76. Mitsuhashi, K., Nosho, K., Sukawa, Y., et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6:9 (2015), 7209–7220.
77. Fan, X., Alekseyenko, A.V., Wu, J., et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut, 2016 Epub 2016-312580.
78. Swidsinski, A., Schlien, P., Pernthaler, A., et al. Bacterial biofilm within diseased pancreatic and biliary tracts. Gut 54:3 (2005), 388–395.
79. Crasta, K., Daly, C.G., Mitchell, D., et al. Bacteraemia due to dental flossing. J. Clin. Periodontol. 36:4 (2009), 323–332.
80. Lockhart, P.B., Brennan, M.T., Sasser, H.C., et al. Bacteremia associated with toothbrushing and dental extraction. Circulation 117:24 (2008), 3118–3125.
81. Ahn, J., Chen, C.Y., Hayes, R.B., Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control 23:3 (2012), 399–404.
82. Ochi, A., Nguyen, A.H., Bedrosian, A.S., et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209:9 (2012), 1671–1687.
83. Guo, Y., Liu, W., Wu, J., Helicobacter pylori infection and pancreatic cancer risk: a meta-analysis. J. Cancer Res. Ther. 12:Supplement (2016), C229–C232.
84. Trikudanathan, G., Philip, A., Dasanu, C.A., et al. Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 12:1 (2011), 26–31.
85. Lindkvist, B., Johansen, D., Borgstrom, A., et al. A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer. BMC Cancer, 8, 2008, 321.
86. Yu, G., Murphy, G., Michel, A., et al. Seropositivity to Helicobacter pylori and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 22:12 (2013), 2416–2419.
87. Chen, X.Z., Schottker, B., Castro, F.A., et al. Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: a ten-year follow-up of the ESTHER cohort study. Oncotarget 7:13 (2016), 17182–17193.
88. Wang, C., Li, J., Pathogenic microorganisms and pancreatic cancer. Gastrointest. Tumors 2:1 (2015), 41–47.
89. Hecht, S.S., Lung carcinogenesis by tobacco smoke. Int. J. Cancer 131:12 (2012), 2724–2732.
90. Gomes, M., Teixeira, A.L., Coelho, A., et al. The role of inflammation in lung cancer. Adv. Exp. Med. Biol. 816 (2014), 1–23.
91. Hua-Feng, X., Yue-Ming, W., Hong, L., et al. A meta-analysis of the association between Chlamydia pneumoniae infection and lung cancer risk. Indian J. Cancer 52:Suppl. 2 (2015), e112–e115.
92. Zhan, P., Suo, L.J., Qian, Q., et al. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. Eur. J. Cancer 47:5 (2011), 742–747.
93. Lin, F.C., Huang, J.Y., Tsai, S.C., et al. The association between human papillomavirus infection and female lung cancer: a population-based cohort study. Medicine (Baltimore), 95(23), 2016, e3856.
94. Lin, T.Y., Huang, W.Y., Lin, J.C., et al. Increased lung cancer risk among patients with pneumococcal pneumonia: a nationwide population-based cohort study. Lung 192:1 (2014), 159–165.
95. Winstone, T.A., Man, S.F., Hull, M., et al. Epidemic of lung cancer in patients with HIV infection. Chest 143:2 (2013), 305–314.
96. Zeng, X.T., Xia, L.Y., Zhang, Y.G., et al. Periodontal disease and incident lung cancer risk: a meta-analysis of cohort studies. J. Periodontol. 87:10 (2016), 1158–1164.
97. Michaud, D.S., Liu, Y., Meyer, M., et al. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. 9:6 (2008), 550–558.
98. Zhang, L., Xiao, H., Zhou, H., et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell. Mol. Life Sci. 69:19 (2012), 3341–3350.
99. Yan, X., Yang, M., Liu, J., et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am. J. Cancer. Res. 5:10 (2015), 3111–3122.
100. Liu, J., Kandasamy, S., Zhang, J., et al. Prebiotic effects of diet supplemented with the cultivated red seaweed Chondrus crispus or with fructo-oligo-saccharide on host immunity, colonic microbiota and gut microbial metabolites. BMC Complement. Altern. Med., 15, 2015, 279.
101. Lavole, A., Toper, C., Belmont, L., et al. [Lung cancer and HIV infection]. Rev. Mal. Respir. 31:2 (2014), 133–141.
102. Hessol, N.A., Martinez-Maza, O., Levine, A.M., et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS 29:10 (2015), 1183–1193.
103. Shcherba, M., Shuter, J., Haigentz, M. Jr., Current questions in HIV-associated lung cancer. Curr. Opin. Oncol. 25:5 (2013), 511–517.
104. Zhai, K., Ding, J., Shi, H.Z., HPV and lung cancer risk: a meta-analysis. J. Clin. Virol. 63 (2015), 84–90.
105. Anantharaman, D., Gheit, T., Waterboer, T., et al. No causal association identified for human papillomavirus infections in lung cancer. Cancer Res. 74:13 (2014), 3525–3534.
106. Brenner, D.R., McLaughlin, J.R., Hung, R.J., Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One, 6(3), 2011, e17479.
107. D'Journo, X.B., Bittar, F., Trousse, D., et al. Molecular detection of microorganisms in distal airways of patients undergoing lung cancer surgery. Ann. Thorac. Surg. 93:2 (2012), 413–422.
108. Dickson, R.P., Erb-Downward, J.R., Huffnagle, G.B., The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7:3 (2013), 245–257.
109. Hosgood, H.D., Sapkota, A.R., Rothman, N., et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutagen. 55:8 (2014), 643–651.
110. Hasegawa, A., Sato, T., Hoshikawa, Y., et al. Detection and identification of oral anaerobes in intraoperative bronchial fluids of patients with pulmonary carcinoma. Microbiol. Immunol. 58:7 (2014), 375–381.
111. Evans, A.S., Causation and disease: the Henle-Koch postulates revisited. Yale J. Biol. Med. 49:2 (1976), 175–195.
112. Byrd, A.L., Segre, J.A., Infectious disease. adapting Koch's postulates. Science 351 (2016), 224–226.
113. Dittmer, D.P., Damania, B., Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J. Clin. Invest. 126 (2016), 3165–3175.
114. Virgin, H.W., The virome in mammalian physiology and disease. Cell 157 (2014), 142–150.